Browse Category

Biotechnology News 5 December 2025 - 8 December 2025

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something
Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Published: December 7, 2025 Inovio Pharmaceuticals (NASDAQ: INO) has quietly turned 2025 into a make‑or‑break year. The small‑cap biotech has completed a Biologics License Application (BLA) for its lead DNA immunotherapy INO‑3107, raised fresh capital through two stock offerings, and
1 2 3 4 5 6 15
Go toTop